ALS is a multisystem disorder affecting motor and cognitive functions. Bulbar-onset ALS (bALS) may be preferentially associated with cognitive and language impairments, compared with spinal-onset ALS (sALS), stemming from a potentially unique neuropathology. The objective of this systematic review was to compare neuropathology findings reported for bALS and sALS subtypes in studies of cadaveric brains. Using Cochrane guidelines, we reviewed articles in MEDLINE, Embase, and PsycINFO databases using standardized search terms for ALS and neuropathology, from inception until July 16th 2016. 17 studies were accepted for analysis. The analysis revealed that both subtypes presented with involvement in motor and frontotemporal cortices, deep cortical structures, and cerebellum and were characterized by neuronal loss, spongiosis, myelin pallor, and ubiquitin+ and TDP43+ inclusion bodies. Changes in Broca and Wernicke areas -regions associated with speech and language processing -were noted exclusively in bALS. Further, some bALS cases presented with atypical pathology such as neurofibrillary tangles and basophilic inclusions, which were not found in sALS cases. Given the limited number of studies, all with methodological biases, further work is required to better understand neuropathology of ALS subtypes.
Introduction
Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease that affects upper and lower motor neurons in the brain, brainstem, and spinal cord, but has also been associated with extra-motor (i.e., cognitive and language) impairments, similar to those found in frontotemporal dementia (FTD) (Phukan et al., 2012; Schreiber et al., 2005) . ALS has two typical presentations at disease onset -approximately 70% of patients present initially with the spinal form of the disease, characterized by muscle weakness and atrophy in the limbs and trunk, when the remaining patients present with bulbar changes, affecting speech and swallowing musculature (Bonduelle, 1975) . Nearly 85% of patients with spinal-onset ALS, however, exhibit bulbar changes with disease progression (Armon and Moses, 1998; Haverkamp et al., 1995) . Approximately 50% of all patients diagnosed with ALS show cognitive and language impairments, while 10% of the patients present with clear signs of FTD (Massman et al., 1996; Ringholz et al., 2005) . ALS is a complex disorder with considerable heterogeneity across affected individuals (Green et al., 2013; Robert et al., 1999) . This heterogeneity is not well understood, however. Addressing the heterogeneity by developing accurate means of patient subtyping (Brooks et al., 1991) is essential for providing more targeted approaches to treatment development, recruitment into clinical trials, and disease management in a clinic (e.g., early identification of bulbar disease in order to plan supportive interventions and predict disease progression).
Bulbar ALS is arguably the most devastating variant of the disease as it is characterized by the fastest decline, the shortest survival (<2 years post diagnosis), and a significantly reduced quality of life (Goldstein et al., 2002; Mitsumoto and Del Bene, 2000) . In addition to the rapid motor decline, some neuroimaging and behavioural studies have observed that bulbar ALS may present with an increased burden of cognitive/language impairments (Lomen-Hoerth et al., 2003; Massman et al., 1996; Ogawa et al., 2009; Ota et al., 2005; Schreiber et al., 2005; Sterling et al., 2010; Strong et al., 1999) . This latter finding remains disputed, however (Gordon et al., 2010a; Taylor et al., 2013) . Two hypotheses have been proposed regarding the association between motor and extramotor abnormalities in ALS, in relation to the disease subtype: 1) it has been suggested that the site of symptom onset may be related to the burden of extra motor impairments, with bulbaronset ALS showing a unique neurodegenerative profile associated with specific and concomitant extramotor impairments (Ichikawa et al., 2008a; Kato et al., 1994; Lomen-Hoerth et al., 2003; Massman et al., 1996; Ogawa et al., 2009; Portet et al., 2001; Schreiber et al., 2005; Strong et al., 1999) ; and 2) the presence of bulbar motor dysfunction, regardless of site of onset, may be associated with extramotor impairments (Massman et al., 1996; Ota et al., 2005; Ringholz et al., 2005; Sterling et al., 2010) . Neither of the two hypotheses has been investigated neuropathologically in cadaveric brain tissue.
Studies that examined the underlying neuropathology in cases with cognitive and language impairments showed that ALS cases typically present with frontotemporal lobar degeneration (FTLD) (Geser et al., 2010; Liscic et al., 2008) . The pathology in the frontotemporal regions consisted of neuronal loss, marked gliosis, and intraneuronal inclusion bodies that were positive for ubiquitin and TAR DNA-binding protein 43 (TDP-43) (Arai et al., 2006; Liscic et al., 2008; Neumann et al., 2006) . The severity and distribution of TDP-43 in the brain has been shown to be well-correlated with antemortem cognitive profiles, often giving insight into the phenotypic presentations of the disease and representing a clinicopathologic spectrum (Mackenzie and Feldman, 2003; Mackenzie, 2007; Prudlo et al., 2016; Yoshida, 2004 ) that ranges from pure motor neuron disease to frontotemporal dementia. The underlying neuropathology, however, has not been well-characterized in the context of bulbar-versus spinal-onset subtypes in the existing literature. An examination of the neuropathological findings from the subtype perspective might shed light into the underlying similarities and/or differences in clinical disease presentations.
This study aimed to contribute to our understanding of ALS subtypes through neuropathological studies of cadaveric brains, and elucidate whether these subtypes are neuropathologically distinct or lie within a spectrum of the same disease. To do this, we conducted a systematic review investigating similarities and differences between neuropathological profiles of bulbar-onset ALS (bALS) and spinal-onset ALS (sALS) by regional distribution and types of pathology.
Methods

Operational definitions
Our search was guided by the following operational definitions, determined a priori: Amyotrophic Lateral Sclerosis, defined as a progressive neurological disease with upper and lower motor neuron involvement determined by clinical, electrophysiological or neuropathologic examination; and cadaveric neuropathological examination, defined as the post-mortem study of disease on the brain and brainstem by gross or microscopic examination.
Search methodology
Studies were identified by searching the Medline (1946 to July 12th, 2016 , Embase (1980 to July 12th, 2016 ), and PsycInfo (2002 to July 12th, 2016 databases. Main search terms included Amyotrophic Lateral Sclerosis, ALS, Lou Gehrig's disease, or motor neuron disease combined with neuropathology, histology, immunohistochemistry, or immunocytochemistry, limited to humans. The search strategy for Amyotrophic Lateral Sclerosis was adapted and modified from a previous Cochrane Review (Dal Bello-Haas and Florence, 2013) . The search terms were adapted for each database to accommodate for differences in subject headings (see Appendix A for full search strategies). Citation lists of included articles were hand-searched for articles relevant to the systematic review.
Study selection
Articles were excluded for this review if they: 1) had no abstract; 2) included no human participants (i.e. animal study); 3) were classified as a tutorial, educational report, or narrative review; 4) were a neuroimaging study (i.e., fMRI, DTI, PET, EEG, MEG, etc.); 5) were a genetic study (i.e., focussing on cases with SOD1/C9ORF72/FUS mutations only); 6) involved a population where >90% of subjects were not diagnosed with ALS (i.e., all forms of motor neuropathies, Alzheimer's Disease, etc.); 7) involved a population where >90% of subjects were diagnosed with an atypical subtype of ALS (i.e., Parkinson-Dementia-ALS of the Guam complex, or juvenile ALS of the Madras subtype); or, 8) did not involve a neuropathological examination, either at microscopic or at a gross macroscopic level, of cadaveric brains (i.e., blood serum analysis, DNA fragmentation, or skin microscopy). Two independent raters (authors SS and KV) reviewed all unique abstracts identified from the primary search. Discrepant ratings were resolved by consensus. All accepted abstracts were brought to full review.
During the full article review, articles were excluded for the same reasons as above and also if they: 1) did not investigate the brain or brainstem (i.e., investigated muscle or spinal cord only), 2) involved a population for which the site of onset was not specified, 3) did not report any bALS cases (i.e., sALS or FTD-onset cases only), or, 4) did not allow for data extraction of bALS cases (i.e., only aggregate data across all subjects of varying onsets). A full review of each article was conducted by the same two independent raters (SS and KV). Discrepant ratings were again resolved by consensus.
Quality assessment
The methodological quality of each included full article was critically appraised using a combination of guidelines designed to improve the quality of reporting non-randomized studies: The Effective Public Health Practice Project (EPHPP) Quality Assessment Tool for Quantitative studies (Thomas et al., 2004) , and the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) statement (Von Elm et al., 2007) . Also, relevant quality assessment questions were adapted from the Cochrane Risk of Bias (Higgins et al., 2011) for domains pertaining to selective enrolment, validity of bALS and sALS group comparisons (i.e., a high risk of bias (ROB) rating for dissimilar sites of tissue sampling, unequal number of patients using artificial respiratory support (ARS) between the two groups, etc.), incomplete clinical information provided (i.e., a high ROB rating for missing data on the cognitive and/or bulbar status of the patients, inadequate genetic testing, etc.), and poor methodological descriptions thereby limiting reproducibility of the study. Risk of bias for each article was judged relative to the dates of gene discovery. For example, articles published after 2011 that did not screen for C9ORF72 mutations were given a high ROB rating, but articles predating 2011 were not (see (Renton et al., 2014) for a chronological timeline of each discovered gene in ALS).
Data extraction
Only full articles that met the inclusion criteria outlined above underwent data extraction by a single rater (SS) and included: 1) study design; 2) diagnosis of the examined group and sample size; 3) demographic variables (i.e. mean age at onset/death, site of initial symptom onset, and sex; 4) disease characteristics (i.e. severity of disease, disease duration, and cognitive status); 5) pathological assessment methods (i.e. sampling sites, staining methods, and immunohistochemistry techniques); and, 6) neuropathological data (i.e. anatomical areas involved, types and extent of pathology). Data on cases with a mixed-motor onset (i.e., limb and bulbar symptoms at initial disease presentation) were excluded. Neuropathological data were extracted for all areas within the cerebral cortex, as well as the hippocampus, amygdala, basal ganglia, thalamus, and cerebellum. For the brainstem, only data pertaining to the selected motor nuclei that innervate bulbar structures (i.e., the trigeminal motor, facial, vagus, and hypoglossal nuclei) were extracted. Data on the spinal cord were beyond the scope of this study and thus not extracted. Partial data extraction (25%) was checked by a second rater (VK) and discrepancies were resolved by consensus.
Results
Literature retrieval
The literature search and study selection flow diagram is shown in Fig. 1 . In addition to the 1377 studies identified through database searching, 5 were found by searching citation lists of included articles. Duplicate abstracts were removed leaving 1208 unique abstracts, of which 880 articles were excluded leaving 328 articles for full review. At this level, an additional 311 were excluded leaving 17 full articles (Averbuch-Heller et al., 1998; Bak et al., 2001a; Bak et al., 2001b; Bodansky et al., 2010; Ishihara et al., 2006; Kamo et al., 1987; Kato et al., 1993; Kato et al., 1994; Kuwahara et al., 2010; Miki et al., 2010; Mochizuki et al., 1995; Nagy et al., 1994; Nakano et al., 2004; Ota et al., 2005; Sugiyama et al., 2013; Troost et al., 1992; Tsuchiya et al., 2000; Tsuchiya et al., 2002) . At abstract screening, the inter-rater agreement was 84.5% for the accept/reject criteria, with a 79% agreement for the reason of rejection. At full text screening, the accept/reject percent agreement was 89.5%, with an 81% agreement for reason of rejection.
Study characteristics
Of all 17 included articles, none directly investigated the neuropathological differences between sALS and bALS. Out of the included studies, however, 11 reported individual neuropathology results for a mixed group of patients-those with bALS or sALS (Ota et al., 2005; Kato et al., 1994; Kamo et al., 1987; Averbuch-Heller et al., 1998; Mochizuki et al., 1995; Bodansky et al., 2010; Sugiyama et al., 2013; Troost et al., 1992; Nagy et al.,1994; Kato et al., 1993; Nakano et al., 2004 )-allowing for a comparison between the two groups ( Table 1 ). The other 6 studies investigated the clinical and neuropathological abnormalities in bALS patients only (Bak et al., 2001b; Ishihara et al., 2006; Kuwahara et al., 2010; Miki et al., 2010; Tsuchiya et al., 2000; Tsuchiya et al., 2002) (Table 3) . Below, we present these two groups of findings separately as the former set of studies allows the comparison of the two disease subtypes, and 
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3.3. Studies allowing direct comparison between bALS and sALS 3.3.1. Study characteristics All 11 included articles had a case series study design. The 11 studies included a total of 123 subjects, with a median of 8 subjects per study and range of 1-24. A total of 32 bALS cases and 91 sALS cases were examined. None of the studies reported any genetic mutations for any of the included subjects as the studies predated the discovery of most ALS genetic mutations. Four (Averbuch-Heller et al., 1998; Kato et al., 1994; Mochizuki et al., 1995; Ota et al., 2005) studies reported patients' bulbar symptomology prior to death, which included severe dysphagia and dysarthria, along with tongue atrophy and fasciculation. The cognitive status of the patients was described in 7 studies (Averbuch-Heller et al., 1998; Kato et al., 1993; Kato et al., 1994; Mochizuki et al., 1995; Nagy et al., 1994; Nakano et al., 2004; Ota et al., 2005) , specifically in 41% of the bALS cases and 40% of the sALS cases, and mostly reported symptomatically as the presence or absence of dementia.
Comparison of clinical outcomes between bALS and sALS
Patient demographics and clinical characteristics of the cases are presented in Table 1 . The average disease duration was significantly shorter (p < 0.05) for bALS cases (M = 29.04 months, SD = 25.98) than sALS cases (M = 51.74 months, SD = 51.59). The two groups were similar in age of onset, except for three studies: two Ota et al., 2005) studies reported bALS patients that were older (>15 years) than the sALS patients at disease onset, and one study (Nakano et al., 2004) reported sALS older than bALS patients.
Across all studies, cognitive abnormalities were reported in 54% of bALS cases and 14% of the sALS cases. Two patients with bALS (disease duration: M = 86.5 months, SD = 71.42) and 7 patients with sALS cases (disease duration: M = 78.57 months, SD = 39.25) received artificial respiratory support (ARS) for more than 1 year prior to death, while 10 bALS patients (disease duration: M = 24.75 months, SD = 18.31) and 21 sALS patients (disease duration: M = 98.93 months, SD = 90.85) did not. ARS status for the remaining 81 cases was not reported.
Patients from both groups, bALS and sALS, presented with spinal symptoms at time of death, including weakness and paralysis of their extremities and/or respiratory difficulties.
Critical appraisal
Methodological quality of the studies with bulbar-onset and spinal-onset patients is addressed in Table 2 . Almost all studies recruited ALS patients using appropriate eligibility criteria. There was no evidence of attrition bias, in that all cases that were tested were reported, and very little evidence of reporting bias, where all pre-specified outcomes, such as all brain regions and stains, were reported.
Of the 11 "mixed-group" studies, only 3 (Averbuch-Heller et al., 1998; Kato et al., 1994; Ota et al., 2005) had an equal number of patients with long-term artificial respiratory support (ARS) in the bulbar-and spinal-onset groups. Four studies (Kamo et al., 1987; Mochizuki et al., 1995; Nagy et al., 1994; Troost et al., 1992) failed to specify the prevalence and duration of ARS, and the remaining 4 (Bodansky et al., 2010; Kato et al., 1993; Nakano et al., 2004; Sugiyama et al., 2013) introduced bias in the neuropathology data by having an unequal proportion of ARS users for the two groups.
Seven of the 11 "mixed-group" studies (Averbuch-Heller et al., 1998; Kato et al., 1993; Kato et al., 1994; Mochizuki et al., 1995; Nagy et al., 1994; Nakano et al., 2004; Ota et al., 2005) reported antemortem cognitive signs of the patients; five of these studies only reported the presence or absence of dementia; another study (Averbuch-Heller et al., 1998) reported "inappropriate behaviour", however, it was unclear whether these were signs of cognitive behavioural dysfunction or pseudobulbar affect; only one study reported specific cognitive changes on an extensive neuropsychological assessment battery . The remaining four studies (Bodansky et al., 2010; Kamo et al., 1987; Sugiyama et al., 2013; Troost et al., 1992) did not mention the cognitive status of their patient population.
Most studies (Bodansky et al., 2010; Kamo et al., 1987; Kato et al., 1993; Nagy et al., 1994; Nakano et al., 2004; Sugiyama et al., 2013; Troost et al., 1992) did not report the presence or absence of bulbar signs (i.e., dysarthria, dysphagia) during the disease course for their patient population.
Five of the 11 "mixed-group" studies (Averbuch-Heller et al., 1998; Kato et al., 1994; Nagy et al., 1994; Nakano et al., 2004; Ota et al., 2005) had methodological biases concerning their neuropathology protocols; the studies either did not uniformly sample the brain regions across cases or did not anatomically define the regions of interest. Furthermore, most studies used a semi-quantitative rating scale to evaluate the severity of neuronal loss and gliosis. This poses another limitation as subjective rating scales were not standardized across studies. The studies also did not indicate whether more than one rater was used to obtain these measures, which suggests a potential detection bias.
Only one of the studies screened for and documented the presence of co-existing FTLD through TDP-43 immunostaining (Bodansky et al., 2010) . Most studies, albeit, were much older and predated the discovery of TDP-43 as the major component of the NCIs in ALS-FTD subtypes (Arai et al., 2006; Neumann et al., 2006) . Four (36%) of the mixed-group studies Nakano et al., 2004; Ota et al., 2005; Troost et al., 1992) stained for ubiquitin, which was the only identifiable component of the inclusions found in ALS-FTD pathology at the time. 10 studies (91%) screened for and documented coexisting neurodegenerative phenomena, such as Alzheimer's Disease (AD) pathology, using various silver staining methods and/or anti-tau sera. None of the studies staged the ADrelated changes using the Braak staging method (Braak and Braak, 1995) .
None of the studies conducted the appropriate genetic testing to validate the observed neuropathological abnormalities, even though two studies (Bodansky et al., 2010; Nagy et al., 1994) discussed SOD1 and TARDBP mutations as potential explanations to the observed pathological findings.
Comparison of neuropathology between bALS and sALS
Regional analyses: The results of the regional analysis between bALS and sALS cases are summarized in Fig. 2 . Four studies suggested differences in the regional profiles of involvement for bALS as compared to sALS patients (Kato et al., 1993; Kato et al., 1994; Nakano et al., 2004; Sugiyama et al., 2013) (Fig. 2A) . These studies suggested an increased prevalence of co-existing FTLD in bALS cases, compared to sALS cases. The unique regional distribution of pathological findings for bALS patients involved, primarily, the extramotor cortical regions, including the frontal, temporal, cingulate, and insular cortices, and frontotemporal white matter (WM). One study also reported pathology in the hippocampus and amygdala in bALS but not in sALS cases (Kato et al., 1993) . Most of these cortical and subcortical areas, however, may not be differentially involved in bALS as 4 other studies in this subgroup of articles reported pathology in these areas for both subtypes (Nagy et al., 1994; Nakano et al., 2004; Ota et al., 2005; Sugiyama et al., 2013) . Of particular interest is the one study that reported differential involvement of the Broca and Wernicke areas -regions that are highly associated with speech and language processing -in bALS cases. These areas were not involved in the sALS cases . While lobular assessment of the frontal and temporal cortices was conducted in other studies, these smaller regions were not individually examined in any of the other included 11 mixed-group studies.
In contrast, all the mixed-group studies (n = 11) reported an overlap in the regional distribution of pathology between bALS and sALS cases-including the frontotemporal cortices and other extra motor cortical regions-and to a similar extent, suggesting that both subtypes were within the same pathological spectrum of disease (see Fig. 2B ). Some studies that reported these overlapping regions of involvement, however, noted differences in the degree of pathological processes, defined as the number of inclusions or severity of neuronal loss and gliosis ranked on a standardized scale. For example, the primary motor cortex was involved in both subtypes, but more notably affected in sALS than bALS in three studies (Kamo et al., 1987; Mochizuki et al., 1995; Sugiyama et al., 2013) , and another study (Averbuch-Heller et al., 1998) reported a greater degree of neuronal loss in the facial and vagus nuclei for the bALS cases as compared to the sALS cases.
Type of pathology: Fig. 3 displays differences in the types of pathology, cumulative across the whole brain, for the two subtypes. Panel A lists four studies that reported unique pathological features for the two disease variants. Specifically, one study reported gliosis, spongiosis, and ubiquitinated inclusions in the whole brain for bALS cases, but not sALS cases ). An ALS diag- Table 2 Summary of methodological quality assessment for studies with bulbar-onset and spinal-onset patients. + = Yes, − = No;? = not reported/unknown/unclear. Fig. 2 . Summary of anatomic regions of involvement between bALS and sALS cases. Summary in panel A (above the solid line) lists studies reporting differences in the regional involvement between ALS variants. Summary in panel B (below the solid line) shows studies reporting shared regions of the brain for both variants. Some studies are shown in both panels as they report results of both types (i.e., differences in some regions but similarities in other regions). CST = corticospinal tract; CC = corpus callosum; Fasc. = fasciculus; Nuc. = nucleus.
nosis was confirmed for these sALS cases based on the loss of Betz cells in the primary motor cortex. Another study reported the presence of senile plaques in the motor cortex of bALS cases, that were absent from sALS cases (Kamo et al., 1987) . Two other studies reported skein-like inclusions and ubiquitinated inclusions that were immunoreactive to TDP-43 in sALS cases, which were absent in bALS cases (Bodansky et al., 2010; Sugiyama et al., 2013) . All 11 studies, however, identified similar types of pathology for both subtypes (Fig. 3B) . The complied data suggested that, on a neurological examination, both bALS and sALS cases displayed an equal extent of neuronal loss, gliosis, and myelin pallor, as well as a comparable amount of bunina bodies, phosphorylated neurofilaments, senile plaques, and skein-like or round intraneuronal inclusions that were positive for ubiquitin and TDP-43.
Neuropathology in bALS-only studies
Study characteristics
All 6 included articles had a case series study design. Across studies, the total number of subjects was 11. All studies reported bulbar symptomology and cognitive status for the patients. 3 . Summary of pathology types compared between bALS and sALS cases. Summary in panel A (above the solid line) lists studies that report unique pathological characteristics for one subtype, but not the other. Summary in panel B (below the solid line) reports studies that indicate similar pathology types for both subtypes. Some studies are shown in both panels as they report results of both types (i.e., differences in some pathology types but similarities in other pathology types). Ubi+ = ubiquitinpositive; NCI = neuronal cytoplasmic inclusions. Incl. = inclusions.
Clinical characteristics
Nine out of 11 cases were diagnosed with ALS-FTD as disease progressed (See Table 3 ). All the bALS patients presented with spinal symptoms at time of death, characterized by weakness and paralysis of their extremities and/or respiratory difficulties. Only one case received ARS for more than one year prior to death. None of the studies reported genetic mutations.
Critical appraisal
Methodological quality of the articles with only bALS cases is depicted in Table 4 . Studies were evaluated using similar quality assessment criteria as the studies with mixed patients, but when appropriate, questions were modified for studies with only bALS patients.
Three out of six studies (Bak et al., 2001b; Ishihara et al., 2006; Tsuchiya et al., 2000) did not specify the presence and duration of ARS, and none of the studies characterized the genetic makeup of the patients or operationally defined the regions of interest using anatomical landmarks.
All of the bALS studies reported bulbar symptomology at some point of the disease course (Bak et al., 2001b; Ishihara et al., 2006; Kuwahara et al., 2010; Miki et al., 2010; Tsuchiya et al., 2000; Tsuchiya et al., 2002) , and all studies reported antemortem cognitive and language signs of the patients. All the bALS studies screened for and documented both co-existing FTLD, by staining against ubiquitin and/or TDP-43, as well as co-existing neurodegenerative phenomena, by staining for AD pathology. Three out of the 6 studies (Bak et al., 2001b; Kuwahara et al., 2010; Tsuchiya et al., 2002) staged the observed AD-related neurofibrillary changes in the brain using Braak's staging methodology.
Neuropathology of bALS
Regional Analysis and Type of Pathology: The neuropathological findings for the studies that investigated exclusively the bALS cases (n = 6) are summarized by the regions of involvement (Fig. 4) , and pathology types (Fig. 5) . Overall, these studies reported similar regions of involvement and types of pathology to the bALS subjects from the mixed-group studies (see Figs. 2 and 3) , including involvement in the Broca area. The findings from this group, however, also noted the presence of neurofibrillary tangles (NFTs) in the hippocampus and amgydala of bALS brains that were reported by 5 studies in which most patients developed FTD with disease progression (see Table 3 ). NFTs were not detected in any of the bALS cases within the mixed-group studies in Fig. 3 . Furthermore, one of the studies (Ishihara et al., 2006) identified basophilic inclusions that did not stain against ubiquitin, tau, or alpha-synuclein antibodies in the frontotemporal regions in the bALS cases. P62, neurofilament or FUS staining was not performed on these inclusions. Table 4 Summary of methodological quality assessment for studies with bulbar-onset patients only. + = Yes, − = No; ? = not reported/unknown/unclear. 
Discussion
The overall goal of this study was to compare and contrast the neuropathological features -both morphology and anatomic distribution -of bALS to sALS by synthesizing the findings from existing literature. This systematic review summarized clinical and neuropathological data from 17 studies. The studies were analysed with respect to two contrasting hypotheses (Abrahams, 2013; Ichikawa et al., 2016; Schreiber et al., 2005) . The first hypothesis proposed categorical pathological differences between bALS and sALS, with the former presenting with substantial extramotor (FTLD) signs as compared to the latter. The second hypothesis proposed that the two subtypes lay within the same spectrum of pathology. The results suggested that both subtypes, defined by the site of symptom onset, presented with comparable FTLD as well as the involvement of the brainstem and deep cortical structures. However, the involvement of regions that have been highly associated with speech and language functions (i.e., Broca and Wernicke areas) may be unique to bALS. When assessing the morphological properties of the pathology, both subtypes presented with neuronal loss and myelin pallor in the cortex and brainstem, along with P62/ubiquitin and/or TDP-43 positive inclusion bodies. In addition, there was evidence of secondary reactive changes, such as gliosis, spongiosis, and microglial activation in both subtypes. Yet, some bALS cases presented with atypical pathology, neurofibrillary tangles and basophilic inclusions, which were not found in any sALS cases. 
Differential involvement of Speech/language regions in bALS
Two studies reported differential involvement of specific regions of interest within the frontal and temporal cortices in bALS patients that were spared in sALS patients. Specifically, small regions related to speech and language processing-Broca and Wernicke areas-were differentially affected in bALS. The antemortem assessment of these patients indicated that these bALS cases initially presented with bulbar motor decline, which later evolved into primary progressive aphasia − a subtype of FTD with language changes. None of the sALS cases across the remaining studies were reported to have changes in these regions. Recent genetic and subsequent neuropathological studies have linked the co-existence of motor neuron disease and FTLD to C9ORF72 repeat expansions (Bigio, 2011; Murray et al., 2011) . Extensive cortical and subcortical frontotemporal involvement may be associated with the C9ORF72 mutation, including reports of involvement of the Broca area (Bede et al., 2013) . Genetic testing for C9ORF72 mutations for the subjects in the two included studies reporting Broca area involvement was not possible as the studies predated the discovery of the gene (Renton et al., 2011) . The data, however, suggest a potential linkage between site of symptom onset, specifically bALS, and particular genotypes, specifically C9ORF72, reinforcing the concept that the pathogenesis of ALS may involve multiple distinct pathways that mediate disease onset and progression (Rothstein, 2009) . Linking neuropathology with genetic information remains high priority for future studies.
The involvement of speech and language processing areas in bulbar ALS has been previously suggested by studies that reported language impairments in ALS that were related to either bulbaronset disease (Ichikawa et al., 2008b; Ichikawa et al., 2011; Lomen-Hoerth et al., 2003) , or to the degree of bulbar motor decline (Ichikawa et al., 2016; Massman et al., 1996; Phukan et al., 2012; Sterling et al., 2010; Yoshizawa et al., 2014) , independent of dementia and motor disabilities. These observations, along with our analysis, suggest a potential co-development of aphasia and bulbar motor symptoms, which, from a pathophysiological perspective, may be directly related to the pattern of disease propagation within the brain. Currently, the factors that govern dissemination of pathology between segregated regions of the brain are unknown. A predominant theory postulates that propagation occurs within neuronal networks that form functional and structural connectomes, along the axonal wiring structure of the brain (Agosta et al., 2015; Evans et al., 2015; Schmidt et al., 2016; Seeley et al., 2009; van den Berg and van den Heuvel, 2016) . A recent large-scale brain connectivity study in ALS has shown that abnormal proteins propagate to anatomic regions that are more closely interconnected by WM tracts than regions that are proximally closer, but with lesser connectivity (Schmidt et al., 2016) . A co-development of aphasia following bulbar changes seems supportive of the connectome hypothesis, in which the pathways connecting the speech motor areas (i.e., the ventral region of the primary motor cortex) to speech/language processing areas may be degenerating in ALS. The speech-language connectome, however, has never been investigated in functional and structural connectivity studies in ALS. This may partially be due to the fact that tracts related to bulbar motor (i.e., corticobulbar tract) and language (i.e., arcuate fasciculus) functions were, until recently, difficult to isolate with existing imaging techniques (Li et al., 2013) and were not anatomically well-defined (Catani and de Schotten, 2008; de Schotten et al., 2011) . Recent methodological advances have opened opportunities for this type of investigation.
While the bALS cases in the included studies presented with obvious bulbar changes during the disease course, all sALS cases also presented with bulbar changes towards the end stage of the disease, characterized by dysarthria and dysphagia. This may explain why some extra-motor cortical regions that are involved in the speech-language connectome, such as the insular and cingulate cortices (Fuertinger et al., 2015) , were pathologically involved in both bALS and sALS cases (Nagy et al., 1994; Nakano et al., 2004) . Future studies would need to examine the pathological profiles of those with fully preserved bulbar function at the time of death (Fujimura-Kiyono et al., 2011) , and compare them with those with bulbar disease, in order to understand the link between bulbar disease, irrespective of onset site, and extramotor involvement.
The comparison is further complicated by the fact that ALS, by definition, is a disease with upper motor neuron (UMN) and lower motor neuron (LMN) pathology. The associated bulbar changes are often characterised clinically by mixed spastic and flaccid dysarthria. The examined studies did not define bulbar signs from the perspective of this distinction. Existing cognitive behavioural studies reported a more prominent cognitive impairment in patients with UMN involvement as compared to those with primarily LMN involvement (Abrahams et al., 1997; David and Gillham, 1986; Gallassi et al., 1985; Gallassi et al., 1989) , suggesting that abnormalities of cognitive/language function may be indica-tors of a subgroup of patients with corticobulbar (UMN) neuronal damage. However, such abnormalities do not seem to be exclusive to the pseudobulbar palsy subtype (Abrahams et al., 1997) and the relation between extramotor dysfunction and LMN bulbar symptoms should be addressed in future studies.
Atypical pathological features in some bALS cases
The diagnostic tools and classification for ALS have been evolving rapidly in recent years. The classic descriptions of ALS focused on the degeneration of the motor neurons, suggesting a motor neuron selective disorder (Hirano, 1991; Lawyer and Netsky, 1953) . However, with the recent discovery of TDP-43 protein (Neumann et al., 2006) and TARDBP mutation (Kabashi et al., 2008; Sreedharan et al., 2008) linking ALS and FTD, a wave of new clinical, genetic, neuropathological and epidemiological studies have suggested that ALS and FTD represent a continuum of disease with shared clinical and pathological features (Lillo et al., 2012; LomenHoerth et al., 2002; Ringholz et al., 2005) including the presence of ubiquitin-positive, TDP-43 positive, tau-and ␣ −synucleinnegative inclusions throughout the central nervous system (Lillo and Hodges, 2009; Neumann et al., 2006) . For the cases included in this review, both bALS and sALS equally presented with typical ALS pathology, including TDP-43 proteinopathy.
Interestingly, however, 5 out of 16 studies that stained for co-existing AD pathology reported the presence of tau-positive neurofibrillary tangles in the hippocampus (Bak et al., 2001a; Kuwahara et al., 2010; Miki et al., 2010; Tsuchiya et al., 2000; Tsuchiya et al., 2002) and amygdala (Tsuchiya et al., 2002) for bALS cases, which were not reported for any of the sALS cases. One study also reported basophilic inclusions in the frontotemporal cortices and cerebellum (Ishihara et al., 2006) for bALS patients. FUS or neurofilament staining was not performed on these inclusions. Both NFTs and basophilic inclusions are not typically seen in classic ALS/FTD subtypes, but more common in other neurodegenerative phenomena (e.g. AD) and atypical forms of ALS, such as Guamanian ALS (Kokubo and Kuzuhara, 2004; Shankar et al., 1989) and Juvenile ALS (Bäumer et al., 2010; Tateishi et al., 2010) . These atypical forms of the disease do not show a greater prevalence of bulbar-onset cases, however (Bäumer et al., 2010; Elizan et al., 1966) . Furthermore, the anatomical distribution of pathology for the bALS patients with these atypical features was not distinctively different when compared with bALS cases with typical pathology; they all presented with a multi-system degeneration, including involvement of the amygdala, basal ganglia, thalamus, and cerebellum (Averbuch-Heller et al., 1998; Kato et al., 1993; Nakano et al., 2004; Ota et al., 2005) . Although the medical history of these cases indicated a seemingly typical ALS, the clinical disease profiles were not sufficiently defined (e.g., cognitive evaluation was not reported), making it difficult to understand the clinical significance of these atypical pathological features. Noteworthy, these atypical inclusions were not observed in any of the sALS patients across all studies with similar staining protocols, even for the cases with similar disease durations, suggesting that these bALS patients may represent a unique subtype that is neuropathologically distinct from typical bALS and sALS.
Quality assessment: limitations of existing studies
Critical appraisal of the individual studies identified a number of methodological limitations of the published studies. They include: 1) a lack of matching between patient groups for their disease characteristics (i.e., use of ARS) and demographics, resulting in large variability in disease durations and severities; 2) insufficient clinical (i.e., both motor and cognitive) description of cases; 3) insufficient documentation of co-existing FTLD and other neurodegenerative phenomena; 4) large variability in the neuropathology methodology across cases within and between studies, and 5) a lack of genetic information. Each of these methodological violations can place a study at substantial risk of bias, affecting the external validity of the findings. For example, the use and duration of ARS may be a confounding factor to the development of extra-motor impairments in ALS (Gordon et al., 2010b; Kim et al., 2007; Massman et al., 1996) , as it can lead to a more widespread pattern of cortical atrophy due to longer disease durations, and consequently, greater disease progression (Whitwell et al., 2006) . Secondly, antemortem bulbar signs were rarely reported and were limited to the mention of dysarthria (Cedarbaum et al., 1999) . The perceptual judgement of the presence of speech changes may not be sensitive to detect more subtle abnormalities in bulbar physiology (Green et al., 2013) . As a result, a clear distinction between cases with bulbar disease and those with pure spinal symptoms may be challenging. Thirdly, studies underdocumented co-existing FTLD in the ALS cases. This may be because most studies predated the discovery of the TDP-43 protein (Neumann et al., 2006) , and the encoding TARDBP gene (Kabashi et al., 2008; Sreedharan et al., 2008 ) that were first to link ALS and FTD. Furthermore, the large variability in neuropathology protocols between subjects may have introduced a detection bias, where the observed pathological differences may be a result of differences in staining methods and sampling sites between subjects, and not a consequence of the disease. Lastly, some pathological abnormalities, especially the atypical features that were reported for some bALS cases, may be directly related to a genetic mutation, which would better account for the pathological differences between groups.
Suggestions for future studies
Synthesizing findings across studies for the purposes of this review was challenging, primarily due to a lack of standardization across the neuropathology protocols. Overall, the existing studies offer limited information for determining if bALS has a unique neurodegenerative profile relative to sALS. In order to adequately distinguish the neuropathology for subtypes in ALS, future studies need to:
(1) Expand and standardize clinical assessments to include antemortem clinical signs and symptoms, with an emphasis on bulbar changes and cognitive testing; (2) Include genetic testing in order to validate the neuropathological findings; (3) Expand and standardize neuropathology protocols regionally to include whole-brain analyses-with regions related to both motor and extramotor functions within the cortex, brainstem, deep cortical structures, and cerebellum-as well as include smaller, more specific, regions of interest within the cortex and WM tracts; (4) Expand and standardize staining methodology to include standardized screening and staging of co-existing neurodegenerative pathology such as Alzheimer's disease, FTLD, and mesial temporal sclerosis; (5) Match patient groups or control for confounding factors, such as specific disease characteristics (i.e., duration of bulbar disease, and duration of ARS) and demographics.
Conclusions
The distinction between bulbar-versus spinal-onset patient groups is common in ALS literature and has implications for clinical management (i.e., predicting disease course and planning symptom management), and allocation to clinical trials. Yet, there is limited knowledge regarding the neuropathological differences between these subtypes. Neuroimaging and behavioural studies have suggested that the two subtypes may be distinct, with greater extramotor involvement in bALS (Lomen-Hoerth et al., 2003; Ogawa et al., 2009; Strong et al., 1999) . However the literature remains inconclusive. This systematic review approached this knowledge gap by comparing neuropathology of the two subtypes across a number of existing studies. The findings revealed a great deal of overlap in the regions of involvement and types of pathology between the two subtypes. However a handful of studies suggested unique distribution and nature of pathology in bALS with a subsequent progression to primary progressive aphasia. Specifically, smaller cortical regions of interest related to speech and language processing seemed differentially involved in this subtype of bulbaronset ALS. Critical appraisal of the literature gleaned that further work is needed as existing studies revealed multiple methodological limitations. In summary, determining if and how subtypes of ALS differ will require future studies designed to have standardized neuropathology protocols with clinical and genetic patient profiles.
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